

**中华人民共和国**  
**湖北省药品监督管理局**  
**出口欧盟原料药证明文件**  
**PEOPLE'S REPUBLIC OF CHINA**  
**HUBEI MEDICAL PRODUCTS ADMINISTRATION**  
**Written confirmation for active substances exported to EU**

Confirmation no. (given by the issuing regulatory authority): HB2000028  
证明文件编号: HB2000028

1. Name and address of site (including building number, where applicable):  
工厂名称与地址(包括建筑物门牌号):

Hubei Gedian Humanwell Pharmaceutical Co., Ltd.  
湖北葛店人福药业有限责任公司

Gedian Economic Development District, E-Zhou City, Hubei Province, 436070  
湖北省鄂州市葛店经济开发区, 邮编: 436070

Manufacturer's licence number(s): 鄂 20160196  
《药品生产许可证》编号: 鄂 20160196

REGARDING THE MANUFACTURING PLANT UNDER (1) OF THE  
FOLLOWING ACTIVE SUBSTANCE(S) EXPORTED TO THE EU FOR  
MEDICINAL PRODUCTS FOR HUMAN USE

项目 1 所列生产企业生产的下列用于出口欧盟的人用原料药

Active substance(s) 原料药名称 (药品通用名)	Activity(ies) 加工方法	Chinese drug approval number <sup>1</sup> 中国药品批准文号
布地奈德 Budesonide	化学合成 Chemical Synthesis	国药准字 H20103795
非那雄胺 Finasteride	化学合成 Chemical Synthesis	国药准字 H20041188
左炔诺孕酮 Levonorgestrel	化学合成 Chemical Synthesis	国药准字 H20103226
黄体酮 Progesterone	化学合成 Chemical Synthesis	国药准字 H20066109
奥卡西平 Oxcarbazepine	化学合成 Chemical Synthesis	国药准字 H20040191

<sup>1</sup>仅供出口的原料药在此栏填写“无”。

Record "none" in case where there is for export-only active substance.

THE ISSUING REGULATORY AUTHORITY HEREBY CONFIRMS THAT:  
兹证明:

This manufacturing plant complies with the requirements of the Chinese Good Manufacturing Practice (= GMP of EU, WHO/ICH Q7);

该企业所实施的 GMP 符合中国药品 GMP 要求, 等同于欧盟、世界卫生组织以及 ICH Q7 药品 GMP 要求;

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure the protection of public health, which is at least equivalent to that in the EU; and

该生产工厂接受定期、严格和透明的监管以及有效地执行药品 GMP 监管措施, 包括反复的飞行检查, 确保保护公众健康, 其水平与欧盟相当; 并且

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

如发现不合规情况, 将会及时通报欧盟有关部门。

Date of inspection of the plant under (1): September 3<sup>rd</sup>, 2020

对该生产工厂检查的日期: 2020 年 09 月 03 日

This written confirmation remains valid until: October 26<sup>th</sup>, 2023

本证明文件的有效期: 2023 年 10 月 26 日

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

关于本证明文件的可靠性可向本局查询确认。

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Chinese law and Directive 2001/83/EC.

按照中国相关法律以及欧盟 2001/83/EC 指令, 生产者应对药品质量负责, 本证明不影响生产者履行该职责。

Address of the issuing regulatory authority: No.19 Gongzheng Road, Wuchang District, Wuhan City, Hubei Province 430071

签发部门地址: 湖北省武汉市武昌区公正路 19 号 430071

Name and function of responsible person: Liu Wenbin, deputy director of the Hubei Medical Products Administration

负责人姓名及职务: 刘文斌, 湖北省药品监督管理局副局长


E-mail, Telephone No., and Fax No.:

电子邮箱、电话、传真:

hbanjian@163.com, 027-87111518

Signature

签字



Stamp of the authority and date  
签发部门盖章与日期

